Builds on momentum following appointment of CEO and completion of Phase III clinical trials for PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”) MISSISSAUGA, Ontario--(BUSINESS WIRE)--Evolve ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results